Clinical impact of amphiregulin expression in patients with epidermal growth factor receptor (EGFR) wild-type nonsmall cell lung cancer treated with EGFR-tyrosine kinase inhibitors

Cancer

Volumn 117, Issue 1, 2011, Pages 143-151

  Chang, Myung Hee ^a   Ahn, Hee Kyung ^a   Lee, Jeeyun ^a   Jung, Chan Kwon ^b   Choi, Yoon La ^a   Park, Yeon Hee ^a   Ahn, Jin Seok ^a   Park, Keunchil ^a   Ahn, Myung Ju ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b The Catholic University of Korea   (South Korea)

Author keywords

amphiregulin; epidermal growth factor receptor; nonsmall cell lung cancer; predictor; tyrosine kinase inhibitors; wild type

Indexed keywords

AMPHIREGULIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BRONCHUS BIOPSY; CANCER CONTROL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTERSTITIAL PNEUMONIA; LUNG NON SMALL CELL CANCER; LUNG RESECTION; LYMPH NODE BIOPSY; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PATIENT SELECTION; PLEURA BIOPSY; PRIORITY JOURNAL; TREATMENT OUTCOME; WEAKNESS; WILD TYPE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; GLYCOPROTEINS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 78650685308     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25560     Document Type: Article

References (30)

1. Schiller JH, Harrington D, Belani CP, et al. Comparison of 4 chemotherapy regimens for advanced nonsmall-cell lung cancer. N Engl J Med. 2002; 346: 92-98.
2. Sequist LV, Martins RG, Spigel D, et al. First-line gefitinib in patients with advanced nonsmall-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol. 2008; 26: 2442-2449.
3. Jackman DM, Yeap BY, Lindeman NI, et al. Phase II clinical trial of chemotherapy-naive patients a≥70 years of age treated with erlotinib for advanced nonsmall-cell lung cancer. J Clin Oncol. 2007; 25: 760-766.
4. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated nonsmall-cell lung cancer. N Engl J Med. 2005; 353: 123-132.
5. Ailawadhi S, Derby L, Natarajan R, Fetterly G, Reid M, Ramnath N., Erlotinib for metastatic nonsmall-cell lung cancer: first-, second- or third-line setting - does it matter? A single-institution experience. Oncology. 2009; 76: 85-90.
6. Inoue A, Kobayashi K, Usui K, et al. First-line gefitinib for patients with advanced nonsmall-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy. J Clin Oncol. 2009; 27: 1394-1400.
7. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004; 304: 1497-1500.
8. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of nonsmall-cell lung cancer to gefitinib. N Engl J Med. 2004; 350: 2129-2139.
9. Cappuzzo F, Hirsch FR, Rossi E, et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in nonsmall-cell lung cancer. J Natl Cancer Inst. 2005; 97: 643-655. (Pubitemid 40812628)
10. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A. 2004; 101: 13306-13311.
11. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009; 361: 947-957.
12. Ahn MJ, Park BB, Ahn JS, et al. Are there any ethnic differences in molecular predictors of erlotinib efficacy in advanced nonsmall cell lung cancer? Clin Cancer Res. 2008; 14: 3860-3866.
13. Hirsch FR, Varella-Garcia M, McCoy J, et al. Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group study. J Clin Oncol. 2005; 23: 6838-6845.
14. Cappuzzo F, Varella-Garcia M, Shigematsu H, et al. Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive nonsmall-cell lung cancer patients. J Clin Oncol. 2005; 23: 5007-5018.
15. Engelman JA, Janne PA, Mermel C, et al. ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive nonsmall cell lung cancer cell lines. Proc Natl Acad Sci U S A. 2005; 102: 3788-3793.
16. Khambata-Ford S, Garrett CR, Meropol NJ, et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol. 2007; 25: 3230-3237.
17. Castillo J, Erroba E, Perugorria MJ, et al. Amphiregulin contributes to the transformed phenotype of human hepatocellular carcinoma cells. Cancer Res. 2006; 66: 6129-6138.
18. Yonesaka K, Zejnullahu K, Lindeman N, et al. Autocrine production of amphiregulin predicts sensitivity to both gefitinib and cetuximab in EGFR wild-type cancers. Clin Cancer Res. 2008; 14: 6963-6973.
19. Busser B, Coll JL, Hurbin A., The increasing role of amphiregulin in nonsmall cell lung cancer. Pathol Biol (Paris). 2009; 57: 511-512.
20. Ishikawa N, Daigo Y, Takano A, et al. Increases of amphiregulin and transforming growth factor-alpha in serum as predictors of poor response to gefitinib among patients with advanced nonsmall cell lung cancers. Cancer Res. 2005; 65: 9176-9184.
21. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000; 92: 205-216.
22. Lee JS, Park K, Kim SW, et al. A randominzed phase III study of gefitinib versus standard chemotherapy (gemcitabine plus cisplatin) as a first-line treatment for never-smokers with advanced or metastatic adenocarcinoma of the lung [abstract]. Paper presented at: 13th World Conference on Lung Cancer; July 21-August 4, 2009; San Francisco, California.
23. Rogers SJ, Box C, Chambers P, et al. Determinants of response to epidermal growth factor receptor tyrosine kinase inhibition in squamous cell carcinoma of the head and neck. J Pathol. 2009; 218: 122-130.
24. Fontanini G, De Laurentiis M, Vignati S, et al. Evaluation of epidermal growth factor-related growth factors and receptors and of neoangiogenesis in completely resected stage I-IIIA nonsmall-cell lung cancer: amphiregulin and microvessel count are independent prognostic indicators of survival. Clin Cancer Res. 1998; 4: 241-249.
25. Ross JS, Slodkowska EA, Symmans WF, Pusztai L, Ravdin PM, Hortobagyi GN., The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist. 2009; 14: 320-368.
26. Amann J, Kalyankrishna S, Massion PP, et al. Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer. Cancer Res. 2005; 65: 226-235.
27. Jacobs B, De Roock W, Piessevaux H, et al. Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab. J Clin Oncol. 2009; 27: 5068-5074.
28. Merchant NB, Voskresensky I, Rogers CM, et al. TACE/ADAM-17: a component of the epidermal growth factor receptor axis and a promising therapeutic target in colorectal cancer. Clin Cancer Res. 2008; 14: 1182-1191.
29. Masago K, Fujita S, Hatachi Y, et al. Clinical significance of pretreatment serum amphiregulin and transforming growth factor-alpha, and an epidermal growth factor receptor somatic mutation in patients with advanced nonsquamous, nonsmall cell lung cancer. Cancer Sci. 2008; 99: 2295-2301.
30. Busser B, Sancey L, Josserand V, et al. Amphiregulin promotes BAX inhibition and resistance to gefitinib in nonsmall-cell lung cancers. Mol Ther. 2010; 18: 528-535.